Skip to main content

Advertisement

SpringerLink
Log in

Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

  • Biomarkers of Heart Failure (WHW Tang and J Grodin, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Impaired renal function may affect natriuretic peptide levels through a variety of factors and mechanisms, such as high prevalence of concomitant vascular and myocardial diseases, reduced clearance, increased risk of volume overload, and different types and solute removal techniques in the setting of dialysis. Nevertheless, accumulating evidence suggests that natriuretic peptide testing may provide insights into management of patients with chronic kidney disease (CKD) and end-stage kidney disease (ESRD) on dialysis, as they have been shown to be independently associated with morbidity and mortality.

Recent Findings

Rising natriuretic peptide levels over time may identify CKD patients more likely to approach ESRD and requiring dialysis initiation. Moreover, serial natriuretic peptide measurements may also be helpful in guiding fluid management in ESRD patients on dialysis. However, since patients with CKD usually have significantly higher and more variable baseline levels of natriuretic peptides than those without CKD, traditional cut-off values may not be applicable, and individualized trajectories should be applied and interpreted in the clinical context.

Summary

Routine clinical use natriuretic peptide testing in the CKD and ESRD settings still needs to be refined and individualized, yet their diagnostic and prognostic values can provide valuable insights into clinical trajectories and potential treatment responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 2018 usrds annual data report: executive summary. Am J Kidney Dis. 2019;73(3, Supplement 1):A9–A22.

  2. Chapter 8: Cardiovascular disease in patients with ESRD. Am J Kidney Dis. 2019;73(3, Supplement 1):S501–S18.

  3. Sud M, Tangri N, Pintilie M, Levey AS, Naimark DMJ. ESRD and death after heart failure in CKD. J Am Soc Nephrol. 2015;26(3):715–22.

    PubMed  Google Scholar 

  4. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36(23):1437–44.

    PubMed  PubMed Central  Google Scholar 

  5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a Report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e61.

    PubMed  Google Scholar 

  6. Breidthardt T, Kalbermatter S, Socrates T, Noveanu M, Klima T, Mebazaa A, et al. Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. Eur J Heart Fail. 2011;13(8):860–7.

    CAS  PubMed  Google Scholar 

  7. Gutierrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem. 2008;54(8):1339–48.

    CAS  PubMed  Google Scholar 

  8. Koch M, Trapp R, Kohnle M, Aker S, Haastert B, Rump LC. B-type natriuretic peptide and severe heart failure at baseline predict overall mortality in incident dialysis patients. Clin Nephrol. 2010;73(1):21–9.

    CAS  PubMed  Google Scholar 

  9. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12(7):1508–15.

    CAS  PubMed  Google Scholar 

  10. Stenberg J, Melin J, Lindberg M, Furuland H. Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients. Hemodial Int. 2019;23(3):402–13.

    PubMed  PubMed Central  Google Scholar 

  11. Lee SW, Song JH, Kim GA, Lim HJ, Kim M-J. Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis. 2003;41(6):1257–66.

    CAS  PubMed  Google Scholar 

  12. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–68.

    CAS  PubMed  Google Scholar 

  13. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195–203.

    CAS  PubMed  Google Scholar 

  14. Bubb KJ, Aubdool AA, Moyes AJ, Lewis S, Drayton JP, Tang O, et al. Endothelial C-type natriuretic peptide is a critical regulator of angiogenesis and vascular remodeling. Circulation. 2019;139(13):1612–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. • Francis GS, Felker GM, Tang WHW. A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol. 2016;67(3):330–7 Contemporary review of clinical perspectives of natriuretic peptide testing.

    PubMed  PubMed Central  Google Scholar 

  16. Cowie MR, Mendez GF. BNP and congestive heart failure. Curr Prob Cardiol. 2003;28(4):264–311.

    Google Scholar 

  17. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316–22.

    PubMed  Google Scholar 

  18. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46(4):610–20.

    CAS  PubMed  Google Scholar 

  20. Jafri L, Kashif W, Tai J, Siddiqui I, Azam I, Shahzad H, et al. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function. BMC Nephrol. 2013;14(117):1471–2369.

    Google Scholar 

  21. • Roberts MA, Hare DL, Sikaris K, Ierino FL. Temporal trajectory of B-type natriuretic peptide in patients with CKD stages 3 and 4, Dialysis, and kidney transplant. Clin J Am Soc Nephrol. 2014;9(6):1024–32 Important paper characterizing trajectories of natriuretic peptides across different CKD stages.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis. 2005;46(1):35–44.

    CAS  PubMed  Google Scholar 

  23. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis. 2003;41(3):571–9.

    CAS  PubMed  Google Scholar 

  24. Luchner A, Hengstenberg C, Löwel H, Riegger GAJ, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers. Hypertension. 2005;46(1):118–23.

    CAS  PubMed  Google Scholar 

  25. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47(3):582–6.

    CAS  PubMed  Google Scholar 

  26. Gergei I, Kramer BK, Scharnagl H, Stojakovic T, Marz W. Renal function, N-terminal pro-B-type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction. Peptides. 2019;111:112–7.

    CAS  PubMed  Google Scholar 

  27. DeFilippi C, van Kimmenade RRJ, Pinto YM. Amino-Terminal Pro–B-Type Natriuretic peptide testing in renal disease. Am J Cardiol. 2008;101(3, Supplement):S82–S8.

    Google Scholar 

  28. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J. 2006;27(3):330–7.

    CAS  PubMed  Google Scholar 

  29. Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R. Comparison of the prognostic usefulness of N-terminal pro–brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol. 2008;102(4):469–74.

    CAS  PubMed  Google Scholar 

  30. • van Kimmenade RRJ, Januzzi JL, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, et al. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol. 2006;48(8):1621–7 Collaborative study assessing diagnostic and prognostic value of natriuretic peptides in acute decompensated heart failure with stratification of renal function.

    PubMed  Google Scholar 

  31. Obineche EN, Pathan JY, Fisher S, Prickett TC, Yandle TG, Frampton CM, et al. Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney Int. 2006;69(1):152–6.

    CAS  PubMed  Google Scholar 

  32. Ludka O, Spinar J, Tomandl J, Konecny T. Comparison of NT-proBNP levels in hemodialysis versus peritoneal dialysis patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(4):325–30.

    CAS  PubMed  Google Scholar 

  33. Al-Hweish A, Sultan SS, Mogazi K, Elsammak MY. Plasma myeloperoxidase, NT-proBNP, and troponin-I in patients on CAPD compared with those on regular hemodialysis. Hemodial Int. 2010;14(3):308–15.

    PubMed  Google Scholar 

  34. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis. 2004;43(5):e21.1–e.6.

    Google Scholar 

  35. Iwashima Y, Horio T, Takami Y, Inenaga T, Nishikimi T, Takishita S, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis. 2002;40(5):974–82.

    CAS  PubMed  Google Scholar 

  36. Scholz SS, Vukadinovic D, Lauder L, Ewen S, Ukena C, Townsend RR, et al. Effects of Arteriovenous fistula on blood pressure in patients with end-stage renal disease: a systematic meta-analysis. J Am Heart Assoc. 2019;8(4):011183.

    Google Scholar 

  37. Kurita N, Mise N, Tanaka S, Tanaka M, Sai K, Nishi T, et al. Arteriovenous access closure in hemodialysis patients with refractory heart failure: a single center experience. Ther Apher Dial. 2011;15(2):195–202.

    PubMed  Google Scholar 

  38. Rao NN, Stokes MB, Rajwani A, Ullah S, Williams K, King D, et al. Effects of Arteriovenous fistula ligation on cardiac structure and function in kidney transplant recipients. Circulation. 2019;139(25):2809–18.

    CAS  PubMed  Google Scholar 

  39. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19(9):1643–52.

    CAS  PubMed  Google Scholar 

  40. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract. 2006;103(4):25.

    Google Scholar 

  41. Sommerer C, Heckele S, Schwenger V, Katus HA, Giannitsis E, Zeier M. Cardiac biomarkers are influenced by dialysis characteristics. Clin Nephrol. 2007;68(6):392–400.

    CAS  PubMed  Google Scholar 

  42. Locatelli F, Hannedouche T, Martin-Malo A, Jacobson SH, Vanholder R, Ronco C, et al. The relationship of NT-proBNP and dialysis parameters with outcome of incident Haemodialysis patients: results from the membrane permeability outcome study. Blood Purif. 2013;35(1–3):216–23.

    CAS  PubMed  Google Scholar 

  43. Laveborn E, Lindmark K, Skagerlind M, Stegmayr B. NT-proBNP and troponin T levels differ after Haemodialysis with a low versus high flux membrane. The Int J Artif Organs. 2015;38(2):69–75.

    CAS  PubMed  Google Scholar 

  44. Koz S, Sahin I, Temel I, Koz ST, Terzi Z. Elimination of NTproBNP in peritoneal dialysis patients. Does peritoneal membrane type make a difference in plasma level and elimination of NTproBNP? Clin Nephrol. 2016;85(5):266–72.

    CAS  PubMed  Google Scholar 

  45. Kojima S, Sakurada T, Uehara M, Okamoto T, Kaneshiro N, Konno Y, et al. Relationship between peritoneal transport characteristics and natriuretic peptides in peritoneal Dialysis patients. Adv Perit Dial. 2015;31:7–10.

    PubMed  Google Scholar 

  46. Kawai Y, Tanaka S, Yoshida H, Hara M, Tsujikawa H, Tsuruya K, et al. Association of B-type natriuretic peptide level with residual kidney function in incident peritoneal Dialysis patients. Perit Dial Int. 2019;39(2):147–54.

    PubMed  Google Scholar 

  47. Bavbek N, Akay H, Altay M, Uz E, Turgut F, Uyar ME, et al. Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients. Perit Dial Int. 2007;27(6):663–8.

    CAS  PubMed  Google Scholar 

  48. Kocyigit I, Gungor O, Unal A, Orscelik O, Eroglu E, Tunca O, et al. The effect of strict volume control on cardiac biomarker and arterial stiffness in peritoneal dialysis patients. Clin Nephrol. 2014;81(4):238–46.

    CAS  PubMed  Google Scholar 

  49. • Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, et al. N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol. 2015;10(4):620–9 Important paper demonstrating relatively tight ranges of natriuretic peptide levels in stable dialysis patients, with acceptable weekly and monthly within-person variability.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Touzot M, Seris P, Maheas C, Vanmassenhove J, Langlois AL, Moubakir K, et al. Mathematical model to predict B-type natriuretic peptide levels in haemodialysis patients. Nephrology. 2019;19(10):13586.

    Google Scholar 

  51. deFilippi CR, Herzog CA. Interpreting cardiac biomarkers in the setting of chronic kidney disease. Clin Chem. 2017;63(1):59–65.

    CAS  PubMed  Google Scholar 

  52. Wang AY. Clinical utility of natriuretic peptides in dialysis patients. Semin Dial. 2012;25(3):326–33.

    CAS  PubMed  Google Scholar 

  53. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001;59(4):1559–66.

    CAS  PubMed  Google Scholar 

  54. Mark PB, Stewart GA, Gansevoort RT, Petrie CJ, McDonagh TA, Dargie HJ, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant. 2006;21(2):402–10.

    CAS  PubMed  Google Scholar 

  55. Khan IA, Fink J, Nass C, Chen H, Christenson R, de Filippi CR. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol. 2006;97(10):1530–4.

    CAS  PubMed  Google Scholar 

  56. David S, Kumpers P, Seidler V, Biertz F, Haller H, Fliser D. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant. 2008;23(4):1370–7.

    CAS  PubMed  Google Scholar 

  57. Mok SRS, Avila J, Milcarek B, Kasama R. The NT-ProBNP test in subjects with end-stage renal disease on hemodialysis presenting with acute dyspnea: is knowing worth the cost? Emerg Med Int. 2013;2013:836497.

    PubMed  PubMed Central  Google Scholar 

  58. Roberts MA, Srivastava PM, Macmillan N, Hare DL, Ratnaike S, Sikaris K, et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol. 2008;3(4):1057–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Niizuma S, Iwanaga Y, Washio T, Ashida T, Harasawa S, Miyazaki S, et al. Clinical significance of increased cardiac troponin T in patients with chronic hemodialysis and cardiovascular disease: comparison to B-type natriuretic peptide and A-type natriuretic peptide increase. Kidney Blood Press Res. 2019;44(5):1050–62.

    CAS  PubMed  Google Scholar 

  60. •• Harrison TG, Shukalek CB, Hemmelgarn BR, Zarnke KB, Ronksley PE, Iragorri N, et al. Association of NT-proBNP and BNP with future clinical outcomes in patients with eskd: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76(2):233–47 Latest meta-analysis summarizing prognostic value at various high cut-off levels of naturetic peptides in patients with ESRD.

    CAS  PubMed  Google Scholar 

  61. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem. 2004;50(12):2279–85.

    CAS  PubMed  Google Scholar 

  62. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;50(6):1009–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Paniagua R, Ventura MD, Avila-Diaz M, Hinojosa-Heredia H, Mendez-Duran A, Cueto-Manzano A, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant. 2010;25(2):551–7.

    CAS  PubMed  Google Scholar 

  64. Guo Q, Barany P, Qureshi AR, Snaedal S, Heimburger O, Stenvinkel P, et al. N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. Am J Nephrol. 2009;29(6):516–23.

    CAS  PubMed  Google Scholar 

  65. Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Christensen JH. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol. 2009;71(4):380–6.

    CAS  PubMed  Google Scholar 

  66. Artunc F, Nowak A, Muller C, Peter A, Heyne N, Haring HU, et al. Mortality prediction using modern peptide biomarkers in hemodialysis patients--a comparative analysis. Kidney Blood Press Res. 2014;39(6):563–72.

    CAS  PubMed  Google Scholar 

  67. Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Investig. 2007;37(5):350–6.

    CAS  Google Scholar 

  68. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease. Heart. 2006;92(10):1518–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R, et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol. 2008;3(2):407–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Koz S, Sahin I, Kayatas M, Koz ST. Comparison of dialysate and plasma NTproBNP in prediction of clinical outcomes of diabetic and nondiabetic peritoneal dialysis patients. Clin Nephrol. 2018;90(1):27–33.

    CAS  PubMed  Google Scholar 

  71. Chao CT, Chiang CK, Huang JW, Hung AK. N-Terminal Pro-Brain Natriuretic Peptide Predicts Long-Term Technique Failure in Patients Undergoing Peritoneal Dialysis. J Clin Med. 2018;7(12).

  72. Kawagoe C, Sato Y, Toida T, Nakagawa H, Yamashita Y, Fukuda A, et al. N-terminal-pro-B-type-natriuretic peptide associated with 2-year mortality from both cardiovascular and non-cardiovascular origins in prevalent chronic hemodialysis patients. Ren Fail. 2018;40(1):127–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007;71(6):548–54.

    CAS  PubMed  Google Scholar 

  74. Winkler K, Wanner C, Drechsler C, Lilienthal J, Marz W, Krane V. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J. 2008;29(17):2092–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Tapolyai M, Faludi M, Reti V, Lengvarszky Z, Szarvas T, Fulop T, et al. Volume estimation in dialysis patients: the concordance of brain-type natriuretic peptide measurements and bioimpedance values. Hemodial Int. 2013;17(3):406–12.

    PubMed  Google Scholar 

  76. Sivalingam M, Vilar E, Mathavakkannan S, Farrington K. The role of natriuretic peptides in volume assessment and mortality prediction in Haemodialysis patients. BMC Nephrol. 2015;16(218):015–0212.

    Google Scholar 

  77. Chazot C, Rozes M, Vo-Van C, Deleaval P, Hurot JM, Lorriaux C, et al. Brain natriuretic peptide is a marker of fluid overload in incident hemodialysis patients. Cardiorenal Med. 2017;7(3):218–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Jacobs LH, van de Kerkhof JJ, Mingels AM, Passos VL, Kleijnen VW, Mazairac AH, et al. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant. 2010;25(1):243–8.

    CAS  PubMed  Google Scholar 

  79. Nongnuch A, Panorchan K, Davenport A. Predialysis NTproBNP predicts magnitude of extracellular volume overload in haemodialysis patients. Am J Nephrol. 2014;40(3):251–7.

    CAS  PubMed  Google Scholar 

  80. Schwermer K, Hoppe K, Radziszewska D, Klysz P, Sawatiuk P, Nealis J, et al. Nterminal proB-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn. 2015;125(7–8):560–9.

    PubMed  Google Scholar 

  81. Sheen V, Bhalla V, Tulua-Tata A, Bhalla MA, Weiss D, Chiu A, et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J. 2007;153(2):041.

    Google Scholar 

  82. Agarwal R. B-type natriuretic peptide is not a volume marker among patients on hemodialysis. Nephrol Dial Transplant. 2013;28(12):3082–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Adachi Y, Nishio A. N-terminal pro-brain natriuretic peptide in prevalent peritoneal dialysis patients. Adv Perit Dial. 2008;24:75–8.

    CAS  PubMed  Google Scholar 

  84. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2007;18(1):321–30.

    CAS  PubMed  Google Scholar 

  85. Granja CA, Tailor PT, Gorban-Brennan N, Francis J, Bekui A, Finkelstein FO. Brain natriuretic peptide and impedance cardiography to assess volume status in peritoneal dialysis patients. Adv Perit Dial. 2007;23:155–60.

    CAS  PubMed  Google Scholar 

  86. Lee JA, Kim DH, Yoo SJ, Oh DJ, Yu SH, Kang ET. Association between serum n-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2006;26(3):360–5.

    CAS  PubMed  Google Scholar 

  87. Chung JH, Yun NR, Ahn CY, Lee WS, Kim HL. Relationship between serum N-terminal pro-brain natriuretic peptide level and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal Dialysis patients. Electrolyte Blood Press. 2008;6(1):15–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Davenport A. Changes in N-terminal pro-brain natriuretic peptide correlate with fluid volume changes assessed by bioimpedance in peritoneal dialysis patients. Am J Nephrol. 2012;36(4):371–6.

    CAS  PubMed  Google Scholar 

  89. Crepaldi C, Rosner M, Teixeira C, Martos LB, Martino FK, Rodighiero MP, et al. Is brain natriuretic peptide a reliable biomarker of hydration status in all peritoneal dialysis patients? Blood Purif. 2014;37(3):238–42.

    CAS  PubMed  Google Scholar 

Download references

Funding

Dr. Tang is partially supported by grants from the National Institutes of Health (R01DK106000, R01HL126827).

Author information

Authors and Affiliations

  1. Kaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA

    Thanat Chaikijurajai & W. H. Wilson Tang

  2. Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Thanat Chaikijurajai

  3. Department of Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA

    Hernan Rincon Choles

Authors
  1. Thanat Chaikijurajai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hernan Rincon Choles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. H. Wilson Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. H. Wilson Tang.

Ethics declarations

Conflict of Interest

Dr. Tang is a consultant for Sequna Medical A.G. and Owkin Inc. has received honorarium from Springer Nature and American Board of Internal Medicine for authorship/editorship, all unrelated to the contents of this paper. All other authors have no relationships to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of Topical Collection on Biomarkers of Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chaikijurajai, T., Choles, H.R. & Tang, W.H.W. Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?. Curr Heart Fail Rep 17, 449–456 (2020). https://doi.org/10.1007/s11897-020-00488-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-020-00488-6

Keywords

Search

Navigation